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TO THE EDITOR
Histamine is the best known pruritogen
in humans and the most commonly used
experimental itch-causing substance. It
induces increased itch responses in the
lesional skin of atopic dermatitis (AD)
patients compared with normal skin
(Ikoma et al., 2006). However,
histamine H1 receptor (H1R) antagonists
frequently fail to relieve the itch in AD
patients as well as it does in patients
with systemic diseases such as kidney
and liver diseases. The lack of amelio-
ration by high-potency H1R antagonists
of different types in patients with itch
suggests that other systems are involved
(Ikoma et al., 2006; Sta¨nder and
Weisshaar, 2012).
Involvement of histamine H4 receptor
(H4R) in histamine-evoked itch in ani-
mal models has been reported (Dunford
et al., 2007; Thurmond et al., 2008).
However, the therapeutic efficacy of
H4R antagonists on the H1R antagonist-
resistant itch in AD is poorly under-
stood. We therefore examined the
therapeutic effects of H4R antagonists
on itch and skin inflammation in AD
using NC/Nga mice, a mouse model of
AD that has been previously described
(Tanaka et al., 2012).
Male NC/Nga mice (Charles River
Japan, Yokohama, Japan), 10 weeks
old, were maintained in clean condi-
tion. All animal procedures were appro-
ved by the institutional Animal Care and
Use Committee of Juntendo University
Graduate School of Medicine. It is gene-
rally accepted worldwide that AD patients
are highly sensitized to house dust
mite allergens (Sanda et al., 1992); and
that house dust mite Dermatophagoides
farinae body (Dfb) and feces are well-
known major environmental allergens
(Matsuoka et al., 1995). We used a Dfb
ointment-induced AD-like mouse model
(Dfb-NC/Nga) to evaluate the thera-
peutic efficacy of H4R antagonists
against itch-related behavior (scratching)
and dermatitis in a mouse model of AD.
Dermatitis was induced by applica-
tion of Dfb ointment (Biostir, Kobe,
Japan) twice a week for 3 weeks as des-
cribed (Yamamoto et al., 2009). Severity
of skin lesion was graded according to
the criteria as described (Matsuda et al.,
1997). Animals that received repeated
application of Dfb ointment to their skin
(Figure 1a) showed higher dermatitis
scores than controls after 3 weeks (data
not shown). After the induction, transe-
pidermal water loss was measured using
a Tewameter TM210 (Courage and Kha-
zawa, Cologne, Germany) and scratch-
ing behavior was observed for 2 hours
using a MicroAct (Neuroscience, Tokyo,
Japan) as described (Inagaki et al., 2003).
Dfb-NC/Nga mice showed significant
loss of transepidermal water and more
scratching bouts (data not shown).
We examined effects of H4R antago-
nists, JNJ7777120 and JNJ28307474, on
dermatitis and scratching behavior in
Dfb-NC/Nga mice. In mice, antagonist
JNJ28307474 shows a longer plasma
half-life than JNJ7777120 (Thurmod
et al., unpublished observations). Mice
that scored over 5 for dermatitis severity
were treated by either intraperito-
neal injection with a vehicle (20%
dimethylsulphoxide and 80% 2-hydro-
xypropyl-b-cyclodextrin in saline) or
H4R antagonists (10 or 30 mg kg
1)
three times per week for 3 weeks
(Figure 1a). Dermatitis score was asses-
sed after each Dfb application, and the
data were expressed as fold change
values over score of dermatitis before
H4R antagonist treatment (baseline) in
each group. No significant amelio-
ration of dermatitis followed treat-
ment by either of these H4R antagonists
(Figure 1b and c). In addition, scratching
behavior was recorded before and after
H4R antagonist treatment (# shown in
Figure 1a). The data were expressed as
fold change values over number of
scratching bouts before the treatment
(baseline) in each group. Behavior ana-
lyses revealed neither treatment inhi-
bited scratching behavior (Figure 1d
and e). Moreover, the fold change
value of scratching bouts significantly
increased by treatment of 30 mg kg1
JNJ28307474 (Figure 1e). Treatment
with JNJ7777120 or JNJ28307474 had
no effect on locomotion activity (Kamo
et al., unpublished observations).
In this study, we found that treatment
with H4R antagonist (JNJ7777120 orAccepted article preview online 20 August 2013; published online 19 September 2013
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H4R, histamine H4 receptor
A Kamo et al.
Effects of H4R Antagonist on Dfb-AD Model
546 Journal of Investigative Dermatology (2014), Volume 134
JNJ28307474) provided no significant
inhibition of scratching behavior or
amelioration of dermatitis in Dfb-NC/
Nga mice. This result is consistent with
a recent study in a canine model of AD
induced by Df house dust mites
(Ba¨umer et al., 2011). Meanwhile,
another study using a model of allergic
dermatitis reported that H4R antagonist
JNJ7777120, but not H1R antagonists,
showed both anti-inflammatory and anti-
pruritic effects in fluorescein-5-isothio-
cyanate-induced dermatitis model
BALB/c mouse (Cowden et al., 2010).
The contact dermatitis model had seve-
ral features common with AD (Takeshita
et al., 2004). Moreover, a more recent
study showed that H1R antagonist olopa-
tadine and H4R antagonist JNJ7777120
improved scratching behavior and skin
inflammation in a model of allergic
dermatitis induced by repeated
challenges with picryl chloride on the
dorsal back of NC/Nga mice (Ohsawa
and Hirasawa, 2012). Thus, although
treatment with JNJ28307474 at high
doses might induce itch because of
off-target effects via histamine H3
receptors or 5-hydroxytryptamine rece-
ptors (Cowden et al., 2010), these
findings suggest that H4R antagonists
are effective against itch of dermatitis in
the hapten-induced model, but not in the
Dfb ointment-induced model. In
addition, a recent study using micro-
dialysis reported elevated levels of
histamine in the induction phase after
topical administration of Df allergen, but
not high levels in the late reactions
(Ba¨umer et al., 2011). Taken together,
these findings imply that histamine may
have only a minor role with other
mediators or mechanisms responsible
for itch and inflammatory reaction in
the pathologic process of AD induced
by environmental allergens such as a
dust mite (Ikoma et al., 2006; Sta¨nder
and Weisshaar, 2012; Kabashima,
2013).
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Figure 1. Effects of histamine H4 receptor (H4R) antagonists on dermatitis and scratching behavior in Dermatophagoides farinae body (Dfb)-NC/Nga mice. (a)
Following repeated application of Dfb ointment for 3 weeks, vehicle or H4R antagonist was administered intraperitoneally (i.p.) three times per week for 3 weeks.
Scratching behavior was recorded before and after treatment (#). (b, c) Dfb-NC/Nga mice were intraperitoneally administered 10 and 30 mg kg 1 JNJ7777120 or
10 and 30 mg kg1 JNJ28307474. No significant improvement of dermatitis was observed in either JNJ7777120 (b) or JNJ28307474 (c). (d, e) Scratching bouts
were not inhibited by either JNJ7777120 (d) or JNJ28307474 (e). The fold change value of scratching bouts significantly increased by treatment at 30 mg kg1
JNJ28307474 (e, *Po0.001). Data (means±standard deviation (SD), n¼7–10) were compared by one-way analysis of variance and Bonferroni’s multiple
comparison test.
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TO THE EDITOR
Lentigo maligna melanoma (LM, i.e.,
in situ melanoma) together with its
invasive form lentigo maligna mela-
noma (LMM) is a subtype of malignant
melanoma with specific and distinct
characteristics compared with the other
subtypes of malignant melanoma (super-
ficial spreading melanoma, nodular
melanoma, and acral lentiginous mela-
noma). In contrast to other subtypes,
LM predominantly occurs on chronically
sun-damaged skin of elderly people
and is the most frequent malignant
melanoma found in the face (Cohen,
1995). Another characteristic feature of
LM is the location of atypical melano-
cytes along the dermal–epidermal junc-
tion, where they are arranged in solitary
units or small nests. Because of these
features, the proportion of tumor cells
within the lesion is usually rather small,
rendering molecular characterization
challenging.
Mutations in the BRAF gene have
been shown to be a common, early
event in melanoma development
(Ko and Fisherm, 2011) and because of
recent advances in the treatment of
metastatic melanoma, the mutational
status of BRAF has become therapy
decisive (Sosman et al., 2012). So far,
only little information is available
on the BRAF V600E and BRAF V600K
mutations in LM. Therefore, the objec-
tive of this study was to determine the
occurrence of mutations in codon 600
of the BRAF gene in a large cohort of
LM patient samples using a highly
sensitive PCR method (Stadelmeyer,
2012).
We analyzed tissue samples from
61 patients (36 women and 25 men;
median age, 73.9 years; age ranging
from 43.5 to 94.5 years). A total of 59
patients had LM and two patients had a
lesion with invasive tumor cells (i.e.,
LMM). LM-adjacent (normal) skin was
available from 39 samples, and DNA
was extracted and analyzed for the
presence of BRAF mutations as descri-
bed in the Supplementary Information.Accepted article preview online 9 August 2013; published online 12 September 2013
Abbreviation: BRAF, v-raf murine sarcoma viral oncogene homolog B1
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